Australia And Russia Are The Two Fastest-Growing Markets For Anti-Infective Drugs

Anti-infective Drugs Market By Country

LONDON, GREATER LONDON, UK, October 23, 2017 /EINPresswire.com/ -- Sales of drugs to treat or prevent infectious diseases are growing at around 17% year on year in Australia and Russia, at double the rate of the next fastest-growing market, India. All these three fast-growing markets are small, however, adding up to only 3.5% of the global total in 2016, while the growth in the large markets of the USA and China averages out at only 3.3%.
Infectious diseases are disorders caused by pathogenic organisms such as bacteria, viruses, fungi or parasites. These diseases can be transmitted or spread from one person to another through direct or indirect contact or indirect contact. Anti-infective drugs are used to treat or prevent these infectious diseases by inhibiting the spread of an infectious agent (static) or by killing the infectious agent (cidal). The main anti-infective drugs include antibiotics, antifungals, antimalarial agents, antituberculosis agents, antiviral agents, penicillins, sulfonamides and tetracyclines.
In the developed world, the incidence of the major kinds of lethal infectious illness has been subtantially reduced despite periodic viral epidemics such as 'flu and the recent return of tuberculosis affecting small numbers of patients. That helps explain the low rate of growth of the anti-infective drugs market in the USA. In the less developed world, fatal diseases such as malaria still have high prevalence, while typhoid is a continuing threat in areas with poor water quality and sanitation. This helps account for high market growth rates in India and (Asiatic) Russia. Climatic conditions can encourage fungal and bacterial illness, an effect seen in parts of Australia.
USA pharmaceuticals companies Gilead Sciences and Merck are the market leaders in anti-infective drug sales, followed by the British drug manufacturer GlaxoSmithKline. Just under 60% of the global total is split among small producers outside the top ten in the market. Generic versions of out-of-patent drugs are significant.
One of the trends shaping the market is innovations of new drugs. Companies in the anti-infective drugs market are working towards constant innovation to provide more effective drugs and also to sustain in the competition of the market. The FDA approved 22 new drugs in 2016. Among them, drugs for infectious diseases held the largest share with 40% (9) approvals. Recently approved antibiotic drugs include Descovy from Gilead Lifesciences, Zepatier from Merck & Co. and others.

Where to Learn More
Read Anti-infective Drugs Market Global Report 2017 from The Business Research Company for information on the following:
Markets Covered: Antibiotics, Antivirals, Antifungals, Others (Antihelmethic, Antiprotozoal)
Companies Mentioned: Pfizer Inc., GlaxosmithKline, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, and Sanofi
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

About The Business Research Company
Visit TheBusinesResearchCompany.com. The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has research professionals at its office in the UK, India, and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. The Business Research Company’s management have more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations. The Business Research Company’s Consultant have master’s qualifications from top institutes and include MBAs, MSCs, CFAs and CAs. The Business Research Company’s Consultants gain training and qualifications from the market Research Society and are trained in advanced research practices, techniques, and ethics.

Oliver Guirdham
The Business Research Company
+44 744 3439350
email us here

Distribution channels: Banking, Finance & Investment Industry, Business & Economy, Healthcare & Pharmaceuticals Industry, World & Regional

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release